Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.” Early-stage life sciences companies are unique for their ability to leverage specialized scientific knowledge and a nimble structure to pursue new, innovative approaches to treat a disease. However, these companies often rely on external investment, such as from venture capital (VC), to be able navigate the cost pressures and considerable risks associated with early-stage drug development.
Life sciences mergers and acquisitions (M&A) represent a clear exit point for VC investors, attracting investment and allowing companies of all sizes to combine their complementary resources, skills and expertise to bring new medicines to patients. Amidst an increasingly challenging investment landscape, preserving M&A is critical to continue supporting the hundreds of pre-clinical companies working to bring new therapies to patients.
Highlights from the blog are included below:
- “Over the past decade, the biopharmaceutical industry has quietly produced a steady drumbeat of significant medical advances…Despite these advances, there’s global pressure to innovate faster. While the U.S. has historically been the global leader in scientific research and development, it now faces increased international competition…”
- “For America to maintain its competitive advantage, it must continue investing in research and clinical development… We believe that venture capital can meaningfully contribute to fill this investment gap, providing support for America’s continued ability to innovate and advance global human health.”
- “This isn’t just our belief — venture-backed companies are driving enhanced R&D productivity and efficiency. Recent data shows that roughly 65% of new medicines originated from outside of large pharmaceutical companies.”
- “We believe the most meaningful breakthroughs in life sciences are rarely achieved in isolation. They’re the result of deep, sustained collaboration — between scientists and clinicians, industry and academia, and increasingly, founders and investors.”
As this blog highlights, life sciences M&A remains a critical pathway for fueling investment and supporting America’s role as a global leader in life sciences innovation. Policymakers must recognize the value of life science M&A and support enforcement policies that encourage these pro-competitive partnerships and the innovative medicines they bring to patients.